SCHEMBL1019918

SCHEMBL1019918

CC1CCCC2CN(C(=O)CN3CCc4nc(N5CCC(F)(F)CC5)ccc4C3)CCN12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 2/20 0.36
DRD3 P35462 2/20 0.33
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
HSD11B1 P28845 1/20 0.32
CDK4 P11802 2/20 0.31
CDK2 P24941 2/20 0.31
CDK6 Q00534 2/20 0.31
HRH3 Q9Y5N1 2/20 0.31
ALDH1A1 P00352 2/20 0.31
PDCD1 Q15116 2/20 0.30
CD274 Q9NZQ7 2/20 0.30
GAA P10253 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30
TLR9 Q9NR96 1/20 0.30
TLR8 Q9NR97 1/20 0.30
TLR7 Q9NYK1 1/20 0.30
S1PR1 P21453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12707159 1.00 ADRA1A (0.36) ADRA1ADRD3PDK1PDK2HSD11B1
SCHEMBL12952827 0.90 ADRA1A (0.33) ADRA1ADRD3HSD11B1CDK4CDK2
SCHEMBL12707157 0.87 ADRA1A (0.36) ADRA1AHRH3ALDH1A1GAASMN1; SMN2
SCHEMBL1018562 0.87 ADRA1A (0.36) ADRA1AHRH3ALDH1A1GAASMN1; SMN2
SCHEMBL1018305 0.86 HRH3 (0.38) ADRA1ADRD3HRH3ALDH1A1
SCHEMBL1017466 0.83 ALDH1A1 (0.34) HRH3ALDH1A1PDCD1CD274GAA
SCHEMBL12707139 0.83 ALDH1A1 (0.34) HRH3ALDH1A1PDCD1CD274GAA
SCHEMBL1016458 0.81 DRD3 (0.36) ADRA1ADRD3HRH3ALDH1A1TLR9
SCHEMBL1017308 0.79 CHRM2 (0.34) CDK4CDK2CDK6HRH3ALDH1A1
SCHEMBL12707147 0.79 CHRM2 (0.34) CDK4CDK2CDK6HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ADRA1A 381/4885DRD3 465/4885PDK1 1536/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ADRA1A 381/4885DRD3 465/4885PDK1 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.